Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469467 | 0.80 | TP53 (0.37) | GPR119ARKIF11FNTAFNTB | |
| SCHEMBL4919275 | 0.80 | HTT (0.49) | KDM1AGPR119KIF11EGLN2GABRA1 | |
| SCHEMBL5361685 | 0.78 | KMT2A (0.51) | GPR119ARKIF11FNTAFNTB | |
| SCHEMBL5354675 | 0.77 | AR (0.47) | AR | |
| SCHEMBL4918581 | 0.76 | KMT2A (0.40) | GPR119ARKIF11FNTAFNTB | |
| SCHEMBL4913965 | 0.75 | KMT2A (0.39) | GPR119ARKIF11FNTAFNTB | |
| SCHEMBL2656845 | 0.75 | CLEC4M (0.46) | FNTAFNTBGABRA1GABRA3 | |
| SCHEMBL4920883 | 0.73 | KMT2A (0.38) | GPR119ARKIF11FNTAFNTB | |
| SCHEMBL5351989 | 0.73 | ALDH1A1 (0.43) | ARFNTAFNTBGABRA1GABRG2 | |
| SCHEMBL539759 | 0.73 | SLC6A3 (0.46) | GPR119KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176906-A1 | Substituted Pyrrole Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20080176906-A1 | Substituted Pyrrole Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20080176906-A1 | Substituted Pyrrole Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | US | disclosed |
| WO-2007145349-A2 | SUBSTITUTED PYRROLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007145349-A2 | SUBSTITUTED PYRROLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-12-21 | — | — | WO | disclosed |
| EP-1824841-A1 | SUBSTITUTED PYRROLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006064944-A1 | SUBSTITUTED PYRROLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176906-A1 | Substituted Pyrrole Derivative | AR, NR5A1, MC2R | KDM1A 438/4885GPR119 400/4885AR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.